Clinical Trials Browser

Nasopharyngeal Carcinoma × Cisplatin × 1 year × Clear all

NCT06064097 2026-03-19

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT02135042 2026-03-18

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Phase 2/3 Active not recruiting

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05063552 2026-03-18

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Phase 2/3 Active not recruiting

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05941741 2026-03-18

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT06029270 2026-03-18

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT07327216 2026-03-04

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT06532279 2026-02-02

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT05524168 2026-01-15

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT07340515 2026-01-14

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT03267498 2026-01-12

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

Phase 2 Completed

40 enrolled 14 charts

Nasopharyngeal Carcinoma

NCT04004871 2025-12-11

Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2 Completed

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT07258979 2025-12-02

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Phase 1/2 Recruiting

Nasopharyngeal Carcinoma, Recurrence

NCT04458909 2025-10-03

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 3 Terminated

15 enrolled 17 charts

Nasopharyngeal Carcinoma

NCT07129772 2025-09-04

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07138989 2025-08-24

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT07136519 2025-08-22

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT02363400 2025-08-19

A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA

Phase 3 Terminated

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT07110558 2025-08-07

PUPA

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT03984357 2025-07-17

PLATINUM

Phase 2 Completed

Nasopharyngeal Carcinoma

NCT04907370 2025-07-16

DIAMOND

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT04823468 2025-06-10

Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma

Phase NA Completed

Nasopharyngeal Carcinoma, Body Weight

NCT05294172 2025-05-30

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06802835 2025-05-16

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT04456322 2025-05-14

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT04974398 2025-04-13

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

296 enrolled 1 FDA

Nasopharyngeal Carcinoma